Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

Author:

Baronciani Luciano1,Peake Ian2,Schneppenheim Reinhard3,Goodeve Anne2,Ahmadinejad Minoo45,Badiee Zahra6,Baghaipour Mohammad-Reza7,Benitez Olga8ORCID,Bodó Imre9,Budde Ulrich10,Cairo Andrea1,Castaman Giancarlo11,Eshghi Peyman5ORCID,Goudemand Jenny12,Hassenpflug Wolf3,Hoorfar Hamid13,Karimi Mehran14,Keikhaei Bijan15,Lassila Riitta16ORCID,Leebeek Frank W. G.17,Lopez Fernandez Maria Fernanda18,Mannucci Pier Mannuccio1,Marino Renato19,Nikšić Nikolas2,Oyen Florian3,Santoro Cristina20ORCID,Tiede Andreas21ORCID,Toogeh Gholamreza22,Tosetto Alberto23ORCID,Trossaert Marc24ORCID,Zetterberg Eva M. K.25ORCID,Eikenboom Jeroen26,Federici Augusto B.27,Peyvandi Flora128ORCID

Affiliation:

1. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy;

2. Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom;

3. Department of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany;

4. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran;

5. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran;

6. Hemophilia-Thalassemia Center, Mashhad University of Medical Science, Mashad, Islamic Republic of Iran;

7. Iranian Hemophilia Comprehensive Treatment Centre, Tehran, Islamic Republic of Iran;

8. Hemophilia Unit, University Vall d’Hebron Hospital, Barcelona, Spain;

9. Department of Internal Medicine and Hematology–Semmelweis University, Budapest, Hungary;

10. Hemostaseology Medilys Laborgesellschaft mbH, Hamburg, Germany;

11. Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy;

12. Univ. Lille, CHU Lille, Haematology and Transfusion, Lille, France;

13. Hemophilia Center, Esfahan University of Medical Science, Esfahan, Islamic Republic of Iran;

14. Hematology Research Center, Shiraz University of Medical Science, Shiraz, Iran;

15. Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;

16. Research Program Unit in Oncology, University of Helsinki, Helsinki University Central Hospital, Coagulation Disorders, Helsinki, Finland;

17. Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands;

18. Complejo Hospitalario Universitario de A Coruña–Servicio de Hematología y Hemoterapia, A Coruña, Spain;

19. Hemophilia and Thrombosis Centre, University Hospital Policlinico, Bari, Italy;

20. Hematology, Hemophilia and Thrombosis Center, University Hospital Policlinico Umberto I, Rome, Italy;

21. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;

22. Thrombosis Hemostasis Research Center–Vali-Asr Hospital–Emam Khameini Complex Hospital, Tehran University of Medical Science, Tehran, Islamic Republic of Iran;

23. Hemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy;

24. Centre Régional de Traitement de l’Hémophilie–Laboratoire d’Hématologie, Nantes, France;

25. Skane University Hospital, Malmo, Sweden;

26. Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands;

27. Hematology and Transfusion Medicine, L. Sacco University Hospital, Department of Oncology and Oncohematology, University of Milan, Milan, Italy; and

28. Department of Pathophysiology and Transplantation and Università degli Studi di Milano and Milan and Italy

Abstract

Abstract Type 3 von Willebrand disease (VWD3) is a rare and severe bleeding disorder characterized by often undetectable von Willebrand factor (VWF) plasma levels, a recessive inheritance pattern, and heterogeneous genotype. The objective of this study was to identify the VWF defects in 265 European and Iranian patients with VWD3 enrolled in 3WINTERS-IPS (Type 3 Von Willebrand International Registries Inhibitor Prospective Study). All analyses were performed in centralized laboratories. The VWF genotype was studied in 231 patients with available DNA (121 [115 families] from Europe [EU], and 110 [91 families] from Iran [IR]). Among 206 unrelated patients, 134 were homozygous (EU/IR = 57/77) and 50 were compound heterozygous (EU/IR = 43/7) for VWF variants. In 22 patients, no or only one variant was found. A total of 154 different VWF variants (EU/IR = 101/58 [5 shared]) were identified among the 379 affected alleles (EU/IR = 210/169), of which 48 (EU/IR = 18/30) were novel. The variants p.Arg1659*, p.Arg1853*, p.Arg2535*, p.Cys275Ser, and delEx1_Ex5 were found in both European and Iranian VWD3 patients. Sixty variants were identified only in a single allele (EU/IR = 50/10), whereas 18 were recurrent (≥3 patients) within 144 affected alleles. Nine large deletions and one large insertion were found. Although most variants predicted null alleles, 21% of patients carried at least 1 missense variant. VWD3 genotype was more heterogeneous in the European population than in the Iranian population, with nearly twice as many different variants. A higher number of novel variants were found in the Iranian VWD3 patients.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3